Further evidence that Lp(a) testing helps boost initiation and intensification of lipid lowering therapy (LLT), with lower LDL-C and fewer cardiovascular (CV) events, comes from a large pooled analysis of the effects of Lp(a) testing in patients with atherosclerotic cardiovascular disease (ASCVD).
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
